Axsome Therapeutics, Inc insider trading
AXSMfinancial statementsForm 4 filings on EDGAR118 transactions since Nov 9, 2024
From August 12, 2026 to November 9, 2026, 0 insiders at Axsome Therapeutics, Inc bought $0 of stock in the open market, and 1 sold $2M. Officers and directors accounted for $0 of purchases and $2M of sales. The last reported transaction was an option exercise by Jacobson Mark L. on September 3, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through September 3, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $2MAug 12, 2026 – Nov 9, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 9, 2026. Insider data through Nov 9, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
118 transactions from November 9, 2024 to November 9, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Jacobson Mark L. | Chief Operating Officer | option exercise | 10,000 | $12.95 | $130K | 10,000 | Sep 3, 2026 |
| Sep 3, 2026 | Jacobson Mark L. | Chief Operating Officer | open-market sale10b5-1 | 10,000 | $208.65 | $2M | 0 | Sep 3, 2026 |
| Aug 6, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 4,660 | $4.95 | $23K | 11,889 | Aug 7, 2026 |
| Aug 6, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 4,660 | $213.95 | $997K | 7,229 | Aug 7, 2026 |
| Aug 5, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 45,004 | $4.95 | $223K | 52,233 | Aug 7, 2026 |
| Aug 5, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 45,004 | $212.01 | $10M | 7,229 | Aug 7, 2026 |
| Jul 1, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 49,666 | $4.95 | $246K | 56,895 | Jul 1, 2026 |
| Jul 1, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 49,666 | $240.25 | $12M | 7,229 | Jul 1, 2026 |
| Jun 11, 2026 | Jeffs Roger | Director | open-market sale10b5-1 | 286 | $249.12 | $71K | 58,367 | Jun 11, 2026 |
| Jun 10, 2026 | Jeffs Roger | Director | open-market sale10b5-1 | 286 | $246.18 | $70K | 58,653 | Jun 11, 2026 |
| Jun 10, 2026 | Mahony Susan | Director | open-market sale10b5-1 | 300 | $246.18 | $74K | 829 | Jun 10, 2026 |
| Jun 10, 2026 | Coleman Mark | Director | open-market sale10b5-1 | 643 | $249.00 | $160K | 30,389 | Jun 10, 2026 |
| Jun 9, 2026 | Mahony Susan | Director | open-market sale10b5-1 | 300 | $237.21 | $71K | 1,129 | Jun 10, 2026 |
| Jun 9, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 49,670 | $4.95 | $246K | 56,899 | Jun 9, 2026 |
| Jun 9, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 49,670 | $241.01 | $12M | 7,229 | Jun 9, 2026 |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | option exercise | 33,000 | $3.50 | $116K | 75,867 | Jun 9, 2026 |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | open-market sale10b5-1 | 33,000 | $240.09 | $8M | 42,867 | Jun 9, 2026 |
| Jun 8, 2026 | Jeffs Roger | Director | option exercise | 1,429 | — | — | 58,939 | Jun 10, 2026 |
| Jun 8, 2026 | Saad Mark E | Director | option exercise | 1,429 | — | — | 11,431 | Jun 10, 2026 |
| Jun 8, 2026 | Mahony Susan | Director | option exercise | 1,429 | — | — | 1,429 | Jun 10, 2026 |
| Jun 8, 2026 | Coleman Mark | Director | option exercise | 1,429 | — | — | 31,032 | Jun 10, 2026 |
| Jun 2, 2026 | Coleman Mark | Director | open-market sale10b5-1 | 5,537 | $223.39 | $1M | 29,603 | Jun 2, 2026 |
| Jun 1, 2026 | Coleman Mark | Director | open-market sale10b5-1 | 6,000 | $230.30 | $1M | 35,140 | Jun 2, 2026 |
| May 29, 2026 | Coleman Mark | Director | open-market sale10b5-1 | 6,000 | $233.46 | $1M | 41,140 | Jun 2, 2026 |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | option exercise | 233 | $12.95 | $3K | 233 | May 5, 2026 |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | open-market sale10b5-1 | 233 | $228.18 | $53K | 0 | May 5, 2026 |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | option exercise | 4,517 | $12.95 | $58K | 4,517 | May 5, 2026 |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | open-market sale10b5-1 | 4,517 | $227.94 | $1M | 0 | May 5, 2026 |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | option exercise | 7,500 | $70.73 | $530K | 7,500 | Apr 23, 2026 |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | open-market sale10b5-1 | 7,500 | $182.42 | $1M | 0 | Apr 23, 2026 |
| Feb 26, 2026 | Coleman Mark | Director | open-market sale10b5-1 | 25,000 | $161.11 | $4M | 47,140 | Feb 27, 2026 |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | option exercise | 35,378 | $2.85 | $101K | 35,378 | Feb 27, 2026 |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | open-market sale10b5-1 | 35,378 | $161.88 | $6M | 0 | Feb 27, 2026 |
| Feb 23, 2026 | Coleman Mark | Director | option exercise | 6,250 | $4.95 | $31K | 72,140 | Feb 25, 2026 |
| Feb 20, 2026 | Coleman Mark | Director | option exercise | 12,485 | $4.95 | $62K | 65,890 | Feb 23, 2026 |
| Feb 10, 2026 | Coleman Mark | Director | option exercise | 5,193 | $8.02 | $42K | 53,405 | Feb 10, 2026 |
| Feb 2, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 32,410 | $185.60 | $6M | 7,229 | Feb 2, 2026 |
| Feb 2, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 32,410 | $8.02 | $260K | 39,639 | Feb 2, 2026 |
| Jan 22, 2026 | Pizzie Nick | Chief Financial Officer | option exercise | 12,000 | $3.50 | $42K | 54,588 | Jan 23, 2026 |
| Jan 22, 2026 | Pizzie Nick | Chief Financial Officer | open-market sale10b5-1 | 12,000 | $187.92 | $2M | 42,588 | Jan 23, 2026 |
| Jan 21, 2026 | Maizel Ari | Chief Commercial Officer | open-market sale10b5-1 | 7,500 | $184.44 | $1M | 0 | Jan 23, 2026 |
| Jan 21, 2026 | Maizel Ari | Chief Commercial Officer | option exercise | 7,500 | $70.73 | $530K | 7,500 | Jan 23, 2026 |
| Jan 7, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 31,261 | $170.38 | $5M | 7,229 | Jan 7, 2026 |
| Jan 7, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 31,261 | $8.02 | $251K | 38,490 | Jan 7, 2026 |
| Jan 6, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 29,450 | $172.33 | $5M | 7,229 | Jan 7, 2026 |
| Jan 6, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 29,450 | $8.02 | $236K | 36,679 | Jan 7, 2026 |
| Jan 5, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | option exercise | 78,703 | $8.02 | $631K | 85,932 | Jan 7, 2026 |
| Jan 5, 2026 | Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | open-market sale10b5-1 | 78,703 | $171.28 | $13M | 7,229 | Jan 7, 2026 |
| Dec 31, 2025 | Saad Mark E | Director | option exercise | 6,231 | $8.02 | $50K | 16,233 | Jan 2, 2026 |
| Dec 31, 2025 | Saad Mark E | Director | open-market sale10b5-1 | 6,231 | $165.18 | $1M | 10,002 | Jan 2, 2026 |
Who the insiders are
Everyone who reported a transaction since November 9, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Tabuteau Herriot | Chief Executive Officer, Director, 10% owner | Aug 6, 2026 | option exercise | 11,889 | — | $76M (11) | 11 of 11 |
| Pizzie Nick | Chief Financial Officer | Jun 9, 2026 | option exercise | 75,867 | — | $10M (2) | 2 of 2 |
| Jacobson Mark L. | Chief Operating Officer | Sep 3, 2026 | option exercise | 10,000 | — | $9M (4) | 4 of 4 |
| Coleman Mark | Director | Jun 10, 2026 | open-market sale | 30,389 | — | $8M (5) | 5 of 5 |
| Saad Mark E | Director | Jun 8, 2026 | option exercise | 11,431 | — | $6M (2) | 2 of 2 |
| Maizel Ari | Chief Commercial Officer | Apr 22, 2026 | option exercise | 7,500 | — | $3M (2) | 2 of 2 |
| Mahony Susan | Director | Jun 10, 2026 | open-market sale | 829 | — | $145K (2) | 2 of 2 |
| Jeffs Roger | Director | Jun 11, 2026 | open-market sale | 58,367 | — | $142K (2) | 2 of 2 |
| Murdock Hunter R. | General Counsel | Jun 23, 2025 | open-market sale | 0 | — | — | — |
Questions
Are Axsome Therapeutics, Inc insiders buying or selling?
Over the twelve months to November 9, 2026, 8 insiders at Axsome Therapeutics, Inc sold $113M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $113M. Only open-market purchases and sales are counted.
Who sold the most Axsome Therapeutics, Inc stock in the last year?
Tabuteau Herriot (Chief Executive Officer, Director, 10% owner) sold $76M in 11 open-market sales over the twelve months to November 9, 2026.
Do Axsome Therapeutics, Inc executives sell under 10b5-1 plans?
30 of the 30 open-market sales in the last twelve months (100%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Axsome Therapeutics, Inc
- Axsome Therapeutics, Inc financial statements
- 1 tracked fund holding AXSM
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.